Department of Neurology, Center for Brain/Mind Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
J Alzheimers Dis. 2024;99(2):489-492. doi: 10.3233/JAD-240195.
As the biological, biomarker-driven framework of Alzheimer's disease (AD) becomes formalized through revised, consensus clinical criteria, clinicians will confront more and more patients in the earliest, asymptomatic stages of disease. The language and diction used by practitioners to characterize these early patients, whether they are diagnosed with AD, and how their condition is documented in medical and legal records have important implications for both their care and their medical-legal status outside of the health system. Investigation is needed urgently to better understand clinicians' views and practices regarding early AD, as we adapt to new disease definitions in this unprecedented era of care.
随着阿尔茨海默病（AD）的生物标志物驱动的框架逐渐正式化，并通过修订后的共识临床标准得到确认，临床医生将在疾病的最早、无症状阶段遇到越来越多的患者。从业者用于描述这些早期患者的语言和措辞，无论他们是否被诊断为 AD，以及他们的病情在医疗和法律记录中的记录方式，对他们的护理以及他们在医疗体系之外的医疗法律地位都有重要影响。随着我们在这个前所未有的护理时代适应新的疾病定义，迫切需要进行调查，以更好地了解临床医生对早期 AD 的看法和实践。
